This article is published in PM360
Published in PM360, CRA’s Ashley Fraser and Owen Male evaluate strategic considerations for manufacturers to shape the future opportunities for combinations in “Strategies for Combination Therapy in Oncology – Part Three: Thinking Outside the Box.” Due to combination therapy, healthcare systems are faced with the challenge of how to value incremental clinical improvements in oncology and how to fund regimens that may be substantially more costly than monotherapy.
The authors examine fundamental hurdles impacting pricing and market access (P&MA) for combinations from the manufacturer perspective, payer value recognition, price determination, and management of access. As combinations become more commonplace in therapeutic areas beyond oncology, manufacturers must consider their role in shaping broader P&MA considerations and policies to achieve an accurate reflection of value for a more sustainable commercial landscape that supports innovation.
